Quantcast

Industry news that matters to you.  Learn more

The Cancer Biomarker Conundrum: Too Many False Discoveries

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.

CWRU Dental Researchers Discover Human Beta Defensins-3 Ignite in Oral Cancer Growth

Detecting oral cancer in its earliest stages can save the lives of the nearly 40,500 people diagnosed annually. But early detection has been difficult.

Case Western Reserve University School of Dental Medicine researchers discovered a biomarker, called human beta defensin-3 (hBD-3), which may serve as an early warning. The defensin is present in all oral cancers and associated with the early stages of oral cancer.

Thermo Fisher Scientific and Intrinsic Bioprobes Announce Alliance in Mass Spectrometric Immunoassay Workflow Development

Thermo Fisher Scientific, Inc., the world leader in serving science, and Intrinsic Bioprobes (IBI) Inc., today announced an alliance to co-develop and market a mass spectrometry solution that will enable researchers to perform quantitative, high-throughput, high-resolution protein biomarker assays. The solution couples the specificity of immunoenrichment with the sensitivity and quantitative capability of mass spectrometry to provide researchers with a more complete, higher-resolution view of the proteome. Initially, via an exclusive reseller agreement, the solution will be applied to the detection of human parathyroid hormone (PTH) and its variants, which may be useful as biomarkers for bone diseases and diseases of the endocrine system.

ART-funded Researchers Find Biomarker Associated with Alzheimer’s

Research led by the Institute of Psychiatry (IoP) King’s College London (KCL) and part-funded by the Alzheimer’s Research Trust has found that certain protein levels in blood could be an early marker of Alzheimer’s.

The international team of scientists also found that higher levels of the protein, called clusterin, were related to more severe and rapid memory loss and greater brain shrinkage. Their findings could lead to development of a blood test to help identify who would benefit from early treatment for Alzheimer’s and also whether treatments were working to delay or prevent brain damage.

New Multiplex Panels from Aushon BioSystems Help Measure Urinary Biomarkers of Kidney Damage during Drug Development

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity. Recent studies identifying biomarkers for kidney injury during pre-clinical testing for certain drugs helped initiate the development of the new panels. Requiring minimal sample volume, the new multiplex biomarker panels address the need for a more rapid, sensitive and accurate method to identify and quantify renal toxicity biomarkers to assist in determining risk.